Combination therapies in MPNs and the potential for personalizing medicine using genomic profiling

Tariq Mughal, MD, FRCP, FACP, Tufts University School of Medicine, Boston, MA, and Buckingham University Medical School, Buckingham, UK, discusses the ongoing efforts to address unmet needs in myeloproliferative neoplasms (MPNs), including the development of JAK2 inhibitor-containing combination therapies. Dr Mughal mentions some combinations being investigated, including ruxolitinib plus pelabresib in the MANIFEST-2 trial (NCT04603495), before emphasizing the importance of personalized medicine and the potential use of genomic profiling to tailor treatment. This interview took place virtually as part of the 16th International Congress on Myeloproliferative Neoplasms (MPNs) in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.